-
Academician Ding Jian appointed as Dean of Zhejiang University Cancer Institute
Time of Update: 2021-03-20
Molecular targeted immunityIn January 2020, focusing on the urgent needs of national strategy, the frontiers of international academics, and the major issues facing human diseases and health, Zhejiang University coordinated the development of disciplines and established the Zhejiang University Cancer Institute, which will screen , diagnose and treat major malignant tumors early.
-
The likelihood of a large-scale collapse of the batch is likely to decrease
Time of Update: 2021-02-16
It's unlikely that the batch will go out of business on a large scale! The number may decrease, but is mainly consolidated and annexed. the collapse of the pharmaceutical batch, it is unlikely 2016 c
-
Hospital market growth in the first half of the year again record low expectations superheroes
Time of Update: 2021-02-09
As the summer drew to a close, looking back at the pharmaceutical industry in the first half of 2018, compared with the turmoil in 2017, under the influence of comprehensive medical reform, generic dr
-
The FDA has issued draft guidelines for THEA labeling updates after the withdrawal of reference drugs
Time of Update: 2021-02-08
In footnote 11 to the draft guidelines, the FDA further recommends: "The FDA has issued proposed regulations that allow ANDA holders to independently submit CBE0-0 supplemental applications based on newly obtained information and to make certain safety-related updates to the labels." The proposed provision is still under review, together with the reviews collected.
-
Fuhong Hanjun Adamu single anti-new adaptive disorder was approved
Time of Update: 2021-01-23
Comprehensive Drug Database (PDB) as of December 2020, Fuhong Hanxuan has invested approximately 270 million yuan in research and development of the new drug, including approved market-listed and staphylactics.
-
Analysis of the reasons why export products are notified: Loss of Korean article (I
Time of Update: 2020-12-23
3. Regulatory response On August 3, 2020, the Ministry of Food and Drug Safety (MFDS) of South Korea conducted a metal foreign (iron powder) inspection of 130 kinds of barley malt powder products circulating in the domestic market of South Korea, confirming whether iron powder removal equipment was installed.
-
Pfizer, the new breast cancer drug, has filed a cdK 4/6 inhibitor new adaptive application in China
Time of Update: 2020-12-18
In China, the company was approved for listing in 2018 with the following adaptations: positive hormone-positive (HR-plus), human skin growth factor-inhibitor 2-negative (HER2-) local late stage or metastatic breast cancer in association with aromatic enzyme inhibitors, as the initial endocrine therapy for post-menopautic female patients.
-
Following the two-vote system, pharmaceutical circulation enterprises ushered in another disaster
Time of Update: 2020-11-14
with the normalization of collection and the promotion of local collection, the pharmaceutical circulation industry will continue to shuffle, there will be more small and medium-sized circulation enterprises out in the future.
-
The FDA last week awarded nearly 20 orphan drug eligibility! Several gene therapies have been shortlisted
Time of Update: 2020-11-12
drugs: genetically modified AAV9 vectors carrying the expression OFF1 protein Research and Development Enterprise: Taysha Gene Therapies Treatment Of Disease: Leigh syndrome (LS) Introduction: Leigh syndrome is a rare genetic neurodegenerative disease.
-
"Good Medicine" Qilu grabs more than 2 billion anti-ED market, rides on the third batch of harvester, "Sorafini" first imitation was approved, breaking the monopoly of the original research; Hengrui
Time of Update: 2020-09-02
Guide: The latest, consistent evaluation of the week dynamics! The third batch of collection will be opened on August 20, "collecting tickets" consistency evaluation work is still in an orderly proces
-
"Medical Speed Reader" rabies vaccine shortage Micro-medical plans to go to Hong Kong IPO in the third quarter of this year
Time of Update: 2020-07-09
Health Insurance Administration issues interim measures for the management of basic medical supplies for medical care; shortage of rabies vaccines in many places; IPO of micro-medicine in The Third
-
Auxiliary drug revenue ratio and other data began to fill in! Hospital assessment landing, drug market change
Time of Update: 2020-06-16
Medical Network June 11 - The Office of the National Health and Health Commission issued a notice on June 9, requesting the collection of second- and third-level public hospitals in 2019 annual perfo
-
Yimin Angko Next Generation Immune Checkpoint Inhibitors Approved for Treatment of Blood Cancers in NMPA Clinical Trials
Time of Update: 2020-06-09
recently, , Yimin Angko Bio Pharmaceutical (http:// Technology (Shanghai) Limited Company (http:// ("Yimin Angko"), announced that the company's new generation of immunocheckpoint inhibitors (it
-
The indication of Viagra "pulmonary hypertension" will be approved in China
Time of Update: 2020-02-05
Wen Jie winter On February 3, CDE formula proposed a batch of priority review and approval lists, including Pfizer's "sildenafil citrate tablets", which were included on the basis of rare diseases, an
-
Looking back on the development and reflection of biopharmaceuticals in 2019
Time of Update: 2020-01-07
In 2019, the biopharmaceutical industry has exciting development and driven industry change, but also has the exercise worthy of reflection! This is a memorable year of 1911 Alzheimer's disease (AD),
